Aducanumab for Alzheimer's disease: The never-ending story that nurses should know
- PMID: 33825339
- PMCID: PMC8186671
- DOI: 10.1002/nop2.878
Aducanumab for Alzheimer's disease: The never-ending story that nurses should know
Conflict of interest statement
Daniel Bressington is Associate Editor of Nursing Open. There are no other conflicts of interest for both authors.
References
-
- Ackley, S. F. , Zimmerman, S. C. , Brenowitz, W. D. , Tchetgen, E. J. , Gold, A. L. , Manly, J. J. , Mayeda, E. R. , Filshtein, T. J. , Power, M. C. , Elahi, F. A. , Brickman, A. M. , & Glymou, M. M. (2021). Effect of reductions in amyloid levels on cognitive change in randomized trials: Instrumental variable meta‐analysis. BMJ, 372, n156. 10.1136/bmj.n156 - DOI - PMC - PubMed
-
- Adams, B. (2021). Lilly hails Alzheimer's win with donanemab, boasting significant slowing of decline [Online]. Available at: https://www.fiercebiotech.com/biotech/lilly‐hails‐alzheimer‐s‐win‐donane... [Online].
-
- Alzheimer’s Association . (2020). https://www.alz.org/email/_internal/downloads/AA‐FDA‐102320.pdf [Online].
-
- Alzheimer’s Research UK . (2019). Behind the headlines: Is a new Alzheimer’s treatment in sight? [Online]. Available at: https://www.alzheimersresearchuk.org/blog/behind‐the‐headlines‐is‐a‐new‐... [Online].
-
- Alzheimer’s Society . (2019). https://www.alzheimers.org.uk/news/2019‐12‐06/alzheimers‐society‐respond... [Online].
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical